Intraductal carcinoma of the prostate can evade androgen deprivation, with emergence of castrate-tolerant cells.
Laura H PorterKohei HashimotoMitchell G LawrenceCarmel PezaroDavid CloustonHong WangMelissa PapargirisHeather ThorneJason Linull nullAndrew RyanSam NordenDaniel A MoonDamien M BoltonShomik SenguptaMark FrydenbergDeclan G MurphyGail P RisbridgerRenea A TaylorPublished in: BJU international (2017)
The study showed that IDC-P is prevalent in aggressive prostate cancer and contains cells that can withstand androgen deprivation. Thus, IDC-P appears functionally relevant in advanced prostate cancer. The presence of IDC-P may be a trigger to develop innovative clinical management plans.